Kyntheum (brodalumab)
- Region
- 🇪🇺 EU
- Active substance
- brodalumab
- Company
- LEO Pharma A/S
- Status
- Authorised
- Therapeutic area
- Psoriasis
- CHMP opinion
- Thu 10 Nov 2016
- EU approval
- Mon 17 Jul 2017
- Application
- EMEA/H/C/003959
- ATC
- L04AC12
- Official record
- www.ema.europa.eu
Indication
Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Kyntheum
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.